Email this article Prognostic significance of primary and interval cytoreductive surgery in late-stage ovarian cancer. A retrospective study
- Authors: Zhurman V.N.1,2, Nechushkina V.M.3,4, Maslennikova A.V.4
-
Affiliations:
- Primorsky Regional Oncological Dispensary
- Pacific State Medical University
- Scientific and Educational Center “Eurasian Oncological Program EAFO”
- Privolzhsky Research Medical University
- Issue: Vol 27, No 2 (2025)
- Pages: 150-156
- Section: Articles
- URL: https://ogarev-online.ru/1815-1434/article/view/344516
- DOI: https://doi.org/10.26442/18151434.2025.2.203174
- ID: 344516
Cite item
Full Text
Abstract
Background. Modern methods of treatment of late-stage ovarian cancer (III–IV) are based on the immediate and maximum surgical removal of all manifestations of the tumor process. However, in some cases, surgical treatment has to be performed after neoadjuvant chemotherapy. Differences in the effectiveness of treatment with both approaches are the subject of discussion in oncogynecology.
Aim. Analysis of overall survival and progression-free survival in patients with late-stage ovarian cancer (IIIC–IVB) depending on the timing and optimality of cytoreductive surgery.
Materials and methods. A retrospective analysis of 467 patients with stage III–IV ovarian cancer who received comprehensive treatment at the Primorsky Regional Oncological Dispensary in the period 2004–2021.
Results. Significant advantages in overall survival and progression-free survival were in patients with ovarian cancer of stages IIIC–IVB, who underwent primary cytoreduction (PCR), compared with patients who underwent interval cytoreduction. With suboptimal PCR volume, the overall survival rate is significantly lower than with full or optimal PCR. There is a tendency to better OS and IBD in patients with PCR in full and optimal volume, compared with patients who underwent PCR in full or optimal volume. Neoadjuvant chemotherapy in patients with serous ovarian carcinoma of low-grade IIIC–IVB stages significantly worsens immediate and long-term treatment results.
Conclusion. In patients with advanced ovarian cancer, performing primary cytoreduction in full or optimal volume is the main treatment. Neoadjuvant chemotherapy is justified only as a therapy of despair in severe general condition or extreme prevalence of the disease.
Full Text
##article.viewOnOriginalSite##About the authors
Varvara N. Zhurman
Primorsky Regional Oncological Dispensary; Pacific State Medical University
Author for correspondence.
Email: varvara2007@yandex.ru
ORCID iD: 0000-0002-6927-3336
Cand. Sci. (Med.), Oncologist
Russian Federation, Vladivostok; VladivostokValentina M. Nechushkina
Scientific and Educational Center “Eurasian Oncological Program EAFO”; Privolzhsky Research Medical University
Email: varvara2007@yandex.ru
ORCID iD: 0000-0002-1855-9692
SPIN-code: 8523-6798
D. Sci. (Med.), Chief Res.; Prof.
Russian Federation, Moscow; Nizhny NovgorodAnna V. Maslennikova
Privolzhsky Research Medical University
Email: varvara2007@yandex.ru
D. Sci. (Med.), Head of Department
Russian Federation, Nizhny NovgorodReferences
- Bercow A, Stewart T, Bregar AJ. Utilization of Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer. JAMA Net Open. 2024;17(10):2439893. doi: 10.1001/jamanetworkopen.2024.39893
- Клинические рекомендации. Рак яичников, рак маточной трубы, первичный рак брюшины. 2020 г. Одобрено Научно-практическим Советом Минздрава РФ. Под ред. А.Д. Каприна. Режим доступа: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf. Ссылка активна на 12.12.2023 [Clinical guidelines. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer. 2020. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. Edited by AD Kaprin. Available at: http://disuria.ru/_ld/13/1326_kr20C48C56C57MZ.pdf. Aссessed: 12.12.2023 (in Russian)].
- Chi DS, Musa F, Dao F. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014
- Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an openlabel, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249-57. doi: 10.1016/S0140-6736(14)62223-6
- Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657-64. doi: 10.1136/ijgc-2020-001640
- Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933-9. doi: 10.1002/cncr.21845
- Румянцев А.А., Тюляндина А.С., Покатаев И.А., и др. Критерии отбора больных с высоким шансом достижения оптимальной и полной циторедукции. Злокачественные опухоли. 2017;7(4):53-62 [Rumyantsev AA, Tjulandina AS, Pokataev IA, et al. Criteria for selection of patients with high chance of complete or optimal debulking in advanced ovarian cancer. Malignant Tumours. 2017;7(4):53-62 (in Russian)].
- Gu H, Zhou R, Ni J, et al. The value of secondary adjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial. Ovarian Reserve. 2020;13(1):70.
- Городнова Т.В., Котив Х.Б., Петрик С.В., и др. Циторедуктивные операции при раке яичников: обзор литературы и анализ опыта клиники за тринадцать лет. Вопросы онкологии. 2018;3:353-65 [Gorodnova TV, Kotiv KhB, Petrik SV, et al. Tsitoreduktivnye operatsii pri rake iaichnikov: obzor literatury i analiz opyta kliniki za trinadtsat let. Voprosy onkologii. 2018;3:353-65 (in Russian)].
- Mueller JJ, Zhou QC, Iasonos A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008
- Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of perioperative outcome. Eur J Cancer. 2016;59:22-33. doi: 10.1016/j.ejca.2016.01.017
- Тюляндина А.С. Клинические и биологические основы выбора рациональной терапии распространенного рака яичников : дис. … д-ра мед. наук. М., 2018 [Tiuliandina AS. Klinicheskie i biologicheskie osnovy vybora ratsionalnoi terapii rasprostranennogo raka iaichnikov : dis. … d-ra med. nauk. Moscow, 2018 (in Russian)].
- Максимов С.Я., Соболев И.В., Хаджимба А.С., и др. Циторедуктивные операции в онкогинекологии. Практическая онкология. 2016;17(3):184-99 [Maksimov SYa, Sobolev IV, Khadzhimba AS, et al. Tsitoreduktivnye operatsii v onkoginekologii. Prakticheskaia onkologiia. 2016;17(3):184-99 (in Russian)].
- Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702-10. doi: 10.1245/s10434-006-9058-0
- Журман В.Н. Оценка эффективности лечения пациенток с раком яичников IIB–IIIB стадий. Казанский медицинский журнал. 2024;105(4):543-50 [Zhurman VN. Evaluation of the treatment effectiveness in patients with stage IIB–IIIB ovarian cancer. Kazan Medical Journal. 2024;105(4):543-50 (in Russian)]. doi: 10.17816/KMJ624991
Supplementary files
